… Expert Perspectives Series – LCA10 and sepofarsen ProQR Expert Perspectives Series on Leber congenital amaurosis 10 and sepofarsen with Aniz Girach and Dr. Ian M. MacDonald. This …
… ProQR Top-line results Phase 1/2 trial of sepofarsen in LCA10 patients ProQR presents Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients. This event is virtually …
ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
… Conference call additional sepofarsen analyses and company strategy update Webcast … additional analyses from the Phase 2/3 Illuminate trial of sepofarsen for LCA10 and provided an update on the company …
… the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10). … – including Illuminate , Insight , and Brighten for sepofarsen, along with Sirius and Helia for ultevursen – will …
The EFF is a growing multiple stakeholder platform for the exchange and sharing of insights and innovations to drive the future of clinical development in inherited retinal diseases. Organized by ProQR
2017 may become a very exciting year for Patricia Biasutto, sepofarsen captain. Her work, developing a novel RNA therapy for Leber congenital amaurosis 10, has progressed steadily. The team expects to start a first clinical trial this year.
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
